These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37558394)

  • 1. Paired risk scores to predict ischaemic and bleeding risk twenty-eight days to one year after an acute coronary syndrome.
    Kerr AJ; Choi Y; Williams MJ; Stewart RA; White HD; Devlin G; Selak V; Lee MAW; El-Jack S; Adamson PD; Fairley S; Jackson RT; Poppe K
    Heart; 2023 Nov; 109(24):1827-1836. PubMed ID: 37558394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study.
    Chen Y; Yin T; Xi S; Zhang S; Yan H; Tang Y; Qian J; Chen J; Su X; Du Z; Wang L; Qin Q; Gao C; Zheng Y; Zhao X; Cheng X; Li Z; Zhang W; Chen H; Wang J; Yang Z; Li H; Liu H; Zhou X; Qu B; Xiang D; Guo Y; Wang L; Nie S; Fu G; Yang M; Cai S
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1194-1204. PubMed ID: 31112635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization.
    Marquis-Gravel G; Neely ML; Valgimigli M; Costa F; Van Klaveren D; Altner R; Bhatt DL; Armstrong PW; Fox KAA; White HD; Ohman EM; Roe MT
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006582. PubMed ID: 32862694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological therapy following acute coronary syndromes in patients with atrial fibrillation: how do we balance ischaemic risk with bleeding risk?
    Fake AL; Harding SA; Matsis PP; Larsen PD
    N Z Med J; 2016 May; 129(1435):39-49. PubMed ID: 27355167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
    Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
    Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
    Valgimigli M; Smits PC; Frigoli E; Bongiovanni D; Tijssen J; Hovasse T; Mafragi A; Ruifrok WT; Karageorgiev D; Aminian A; Garducci S; Merkely B; Routledge H; Ando K; Diaz Fernandez JF; Cuisset T; Nesa Malik FT; Halabi M; Belle L; Din J; Beygui F; Abhyankar A; Reczuch K; Pedrazzini G; Heg D; Vranckx P;
    Eur Heart J; 2022 Sep; 43(33):3100-3114. PubMed ID: 35580836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.
    Bardají A; Leal M; Arrarte V; Garcia-Moll X; Pérez de Isla L; Bueno H
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27885830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; Frati G; Biondi-Zoccai G; De Luca G
    J Thromb Thrombolysis; 2020 Aug; 50(2):337-354. PubMed ID: 31919736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
    Spinthakis N; Farag M; Akhtar Z; Gorog DA
    Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of PRECISE-DAPT score with ischaemic outcomes in patients taking dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis.
    Clifford CR; Boudreau R; Visintini S; Orr N; Fu AYN; Malhotra N; Barry Q; So DYF
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):511-518. PubMed ID: 34849686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the performance of the PRECISE-DAPT and PARIS risk scores for predicting one-year out-of-hospital bleeding in acute coronary syndrome patients.
    Abu-Assi E; Raposeiras-Roubin S; Cobas-Paz R; Caneiro-Queija B; Martínez-Reglero C; Rodríguez-Rodríguez JM; Baz A; Íñiguez-Romo A
    EuroIntervention; 2018 Mar; 13(16):1914-1922. PubMed ID: 29131804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Selvaraj V; Chatterjee S; Hirai T; Abbott JD; Bavishi C
    Catheter Cardiovasc Interv; 2022 Dec; 100(7):1151-1158. PubMed ID: 36326115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease.
    Witberg G; Plakht Y; Bental T; Feldman BS; Leventer-Roberts M; Levi A; Gabay H; Balicer R; Gerber Y; Kornowski R
    PLoS One; 2019; 14(2):e0209661. PubMed ID: 30763340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
    Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients.
    Han J; Zhang Y; Shi X; Lin B; Zhang Y; Zhang R; Wang Y; Yan J; Lin Y
    Glob Heart; 2023; 18(1):11. PubMed ID: 37228657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic and Bleeding Profile of Patients on Dual Antiplatelet Therapy beyond 1 Year of Index Acute Coronary Syndrome / Percutaneous Intervention.
    Husain MA; Chaudhary SC; Singh A; Pradhan A; Sawlani KK
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
    Obayashi Y; Watanabe H; Morimoto T; Yamamoto K; Natsuaki M; Domei T; Yamaji K; Suwa S; Isawa T; Watanabe H; Yoshida R; Sakamoto H; Akao M; Hata Y; Morishima I; Tokuyama H; Yagi M; Suzuki H; Wakabayashi K; Suematsu N; Inada T; Tamura T; Okayama H; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    Circ Cardiovasc Interv; 2022 Aug; 15(8):e012004. PubMed ID: 35912647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
    Haller PM; Sulzgruber P; Kaufmann C; Geelhoed B; Tamargo J; Wassmann S; Schnabel RB; Westermann D; Huber K; Niessner A; Gremmel T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):226-236. PubMed ID: 31198930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.